{{Rsnum
|rsid=2357928
|Gene=CACNB2
|Chromosome=10
|position=18549641
|Orientation=plus
|GMAF=0.3792
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=132
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 28.3 | 44.2 | 27.4
| HCB | 48.9 | 44.5 | 6.6
| JPT | 47.8 | 33.6 | 18.6
| YRI | 56.5 | 38.1 | 5.4
| ASW | 57.9 | 38.6 | 3.5
| CHB | 48.9 | 44.5 | 6.6
| CHD | 45.9 | 41.3 | 12.8
| GIH | 10.9 | 43.6 | 45.5
| LWK | 50.0 | 40.0 | 10.0
| MEX | 19.3 | 50.9 | 29.8
| MKK | 46.8 | 42.9 | 10.3
| TSI | 31.4 | 52.9 | 15.7
| HapMapRevision=28
}}{{PMID Auto
|PMID=21156931
|Title=Genetic Variation in the {beta}2 Subunit of the Voltage-Gated Calcium Channel and Pharmacogenetic Association With Adverse Cardiovascular Outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES)
|OA=1
}}

{{PMID Auto
|PMID=23744328
|Title=[Association between CACNB2 gene polymorphisms and essential hypertension]
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}